IMR Press / FBL / Volume 28 / Issue 5 / DOI: 10.31083/j.fbl2805098
Open Access Review
SGLT2i in Patients with Type 1 Diabetes: Benefits, Risks, and Preventive Strategies
Show Less
1 Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Henan Key Laboratory of Rare Diseases, 471003 Luoyang, Henan, China
2 Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Zhejiang University School of Medicine, 310000 Hangzhou, Zhejiang, China
*Correspondence: (Pengfei Shan); (Hongwei Jiang)
Front. Biosci. (Landmark Ed) 2023, 28(5), 98;
Submitted: 12 November 2022 | Revised: 5 January 2023 | Accepted: 13 January 2023 | Published: 22 May 2023
(This article belongs to the Special Issue An Update on Sodium Glucose Co-Transporters)
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Sodium-glucose cotransporter inhibitors (SGLT2i) play an increasingly important role in type 2 diabetes mellitus (T2DM) due to their significant cardiovascular benefits and renal protection in addition to their hypoglycemic effects. In recent years, the application of SGLT2i in patients with type 1 diabetes mellitus (T1DM) has attracted more and more attention. Studies have shown that SGLT2i improves glycemic control, reduces total daily insulin dose, decrease body weight in patients with T1DM, without increasing the risk of severe hypoglycemia. SGLT2i also reduces urinary protein levels, prevents atherosclerosis, and offers cardiorenal benefits in patients with T1DM. But simultaneously, they significantly increased risk of diabetic ketoacidosis (DKA), which leads to increased hospitalization and mortality. Hence SGLT2i is recommended to T1DM who are motivated, adhere to self-glucose monitoring, well-trained in identifying DKA, and closely followed to ensure the efficacy and safety.

type 1 diabetes mellitus
diabetes kidney disease
cardiovascular disease
diabetic ketoacidosis
2001027A/Medical and Health Research Project in Luoyang
2018YFC1311705/National Key R&D Program of China
Fig. 1.
Back to top